Implementing VTE Prevention in Ambulatory Cancer Care
Trial Snapshot
- Phase
- Not Applicable
- Status
- Enrolling By Invitation
- Sponsor
- University of Vermont
- Enrollment
- 25
- Locations
- 2
- Primary Endpoint
- Documented VTE risk assessment
Study Overview
Brief Summary
assess effectiveness of a , compared with usual care, to assess
The goal of this study is to learn if a modified clinical program can improve adherence to guideline recommendations for prevention of venous thromboembolism in ambulatory patients with cancer. The main question[s] it aims to answer are:
Does the modified program improve number of ambulatory oncology patients starting systemic treatment getting VTE risk-assessment? Does the modified program improve the number of patients receiving appropriate preventative anticoagulation? Researchers will compare to usual care (no clinical program).
Participant clinicians will be asked to
- receive education about VTE prevention recommendations
- carry out risk assessment, anticoagulation discussions, and document the results Participant patients will receive care from clinicians participating in the study as part of their cancer care.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Clinicians: practicing oncologist at study clinic site (UVMMC)
- •Patients: diagnosis of cancer; starting new systemic cancer-directed therapy at a study clinic site under the direction of the enrolled clinician
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Documented VTE risk assessment
Time Frame: 30 days after new patient appointment
Proportion of new patients who have documented VTE risk assessment
Secondary Outcomes
- Appropriate thromboprophylaxis(30 days after new patient appointment)
Investigators
Karlyn Martin
Associate Professor of Medicine
University of Vermont